| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6168217 | Urology | 2012 | 5 Pages |
Abstract
We observed heterogeneous outcomes among patients within the National Comprehensive Cancer Network intermediate- and high-risk groups. The BCR-free survival rates were superior for men with an advanced clinical stage compared with those with an advanced Gleason score or elevated PSA level. This within-group heterogeneity must be considered when choosing the treatment modality and predicting an individual patient's prognosis.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Adam C. Reese, Phillip M. Pierorazio, Misop Han, Alan W. Partin,